Denali Therapeutics (DNLI) Competitors $11.06 -0.41 (-3.53%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DNLI vs. ROIV, LNTH, BBIO, RVMD, LEGN, TGTX, SRPT, AXSM, BPMC, and TLXShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Roivant Sciences (ROIV), Lantheus (LNTH), BridgeBio Pharma (BBIO), Revolution Medicines (RVMD), Legend Biotech (LEGN), TG Therapeutics (TGTX), Sarepta Therapeutics (SRPT), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Roivant Sciences Lantheus BridgeBio Pharma Revolution Medicines Legend Biotech TG Therapeutics Sarepta Therapeutics Axsome Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Roivant Sciences (NASDAQ:ROIV) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Do analysts prefer ROIV or DNLI? Roivant Sciences presently has a consensus price target of $17.50, indicating a potential upside of 92.73%. Denali Therapeutics has a consensus price target of $37.57, indicating a potential upside of 227.56%. Given Denali Therapeutics' higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Denali Therapeutics 0 Sell rating(s) 2 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.94 Do insiders and institutionals have more ownership in ROIV or DNLI? 64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by company insiders. Comparatively, 7.9% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ROIV or DNLI more profitable? Denali Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-119.54% -14.05% -12.81% Denali Therapeutics N/A -32.94%-30.04% Does the MarketBeat Community favor ROIV or DNLI? Denali Therapeutics received 411 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.26% of users gave Roivant Sciences an outperform vote while only 68.48% of users gave Denali Therapeutics an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5478.26% Underperform Votes1521.74% Denali TherapeuticsOutperform Votes46568.48% Underperform Votes21431.52% Does the media favor ROIV or DNLI? In the previous week, Denali Therapeutics had 9 more articles in the media than Roivant Sciences. MarketBeat recorded 16 mentions for Denali Therapeutics and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.27 beat Denali Therapeutics' score of 0.90 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, ROIV or DNLI? Roivant Sciences has higher earnings, but lower revenue than Denali Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$122.59M52.85$4.35B-$0.15-60.53Denali Therapeutics$330.53M5.04-$145.22M-$2.57-4.46 Which has more risk and volatility, ROIV or DNLI? Roivant Sciences has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. SummaryDenali Therapeutics beats Roivant Sciences on 9 of the 17 factors compared between the two stocks. Remove Ads Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.67B$2.71B$5.08B$6.91BDividend YieldN/A1.52%5.34%4.22%P/E Ratio-4.1628.5321.3217.05Price / Sales5.04402.11345.2285.96Price / CashN/A168.6838.1534.64Price / Book1.553.296.023.66Net Income-$145.22M-$72.06M$3.19B$247.27M7 Day Performance-16.52%-12.54%-8.86%-9.80%1 Month Performance-31.28%-25.24%-6.83%-12.84%1 Year Performance-41.00%-36.93%0.66%-10.68% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.1565 of 5 stars$11.07-3.5%$37.57+239.6%-39.8%$1.61B$330.53M-4.01430Gap UpROIVRoivant Sciences2.0252 of 5 stars$10.09-2.8%$17.10+69.5%-21.9%$7.20B$122.59M-67.26860LNTHLantheus4.2852 of 5 stars$97.60+1.5%$129.43+32.6%+56.4%$6.68B$1.53B16.24700News CoveragePositive NewsBBIOBridgeBio Pharma4.5162 of 5 stars$34.57-1.5%$52.64+52.3%+6.6%$6.57B$221.90M-12.13400Positive NewsGap UpRVMDRevolution Medicines3.459 of 5 stars$35.36-5.3%$66.31+87.5%-2.4%$6.57B$742,000.00-9.85250Analyst ForecastNews CoveragePositive NewsGap UpLEGNLegend Biotech2.58 of 5 stars$33.93-3.2%$79.00+132.8%-43.9%$6.23B$627.24M-35.721,070Analyst ForecastNews CoveragePositive NewsGap UpTGTXTG Therapeutics3.2059 of 5 stars$39.43-1.1%$40.67+3.1%+137.3%$6.19B$329.00M-394.26290News CoveragePositive NewsGap UpSRPTSarepta Therapeutics4.7356 of 5 stars$63.82-9.4%$164.05+157.0%-61.0%$6.19B$1.90B51.061,314Quiet Period ExpirationGap UpHigh Trading VolumeAXSMAxsome Therapeutics4.6534 of 5 stars$116.63-1.6%$167.64+43.7%+35.3%$5.69B$385.69M-19.47380Analyst ForecastAnalyst RevisionNews CoverageGap UpBPMCBlueprint Medicines2.5585 of 5 stars$88.51-0.2%$124.95+41.2%-13.5%$5.66B$508.82M-81.95640Analyst ForecastPositive NewsGap UpTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.76-2.8%$22.00+31.3%N/A$5.65B$783.21M0.00N/AGap Up Remove Ads Related Companies and Tools Related Companies Roivant Sciences Competitors Lantheus Competitors BridgeBio Pharma Competitors Revolution Medicines Competitors Legend Biotech Competitors TG Therapeutics Competitors Sarepta Therapeutics Competitors Axsome Therapeutics Competitors Blueprint Medicines Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNLI) was last updated on 4/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Silver isn't just a safe haven for your wealth—it's a critical resource in the global tech and energy race. Wi...GoldenCrest Metals | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DNLI Stock Free DNLI Stock Alerts